Karyon Ltd - Targeting peptides

Karyon Ltd's operations focus on the discovery, IP protection and early development of carrier peptides that target specific tissues. The targeting peptides are identified from ex vivo patient tumour tissue and further synthetically modified at Karyon Ltd. Linking a diagnostic marker or therapeutic regimen to the targeting peptide enriches compound concentration in the target organ.


Karyon targeting unitTarget indications
Karyon TCTP
Tumour cell targeting peptides
Sarcoma, melanoma, kaposi's sarcoma
Karyon AETP
Activated endothelium targeting peptides
Conditions of angiogenic origin
Karyon Thx-1
Non small cell lung cancer targeting peptide
Non small cell lung cancer
Karyon LMC
Lung metastases
Colon cancer lung metastases
Karyon OrCa
Oral cancer targeting peptides
Lingual and gingival cancer forms
Karyon LyMe
Lymph sentinel node metastases
Head and neck lymph sentinel node metastases

Karyon Ltd's scientists are pleased to assist your company's diagnostic or therapeutic compound find its tumour target.

Products and Services

Contact Details

Karyon Ltd
Tel: + 358 9 319 36400/36401
Fax: + 358 9 319 36415
Email: rabbe.slatis@karyon.fi
URL: www.karyon.fi

Make An Enquiry
First Name

Last Name

Email Address


Privacy Policy
We have updated our privacy policy. In the latest update it explains what cookies are and how we use them on our site. To learn more about cookies and their benefits, please view our privacy policy. Please be aware that parts of this site will not function correctly if you disable cookies. By continuing to use this site, you consent to our use of cookies in accordance with our privacy policy unless you have disabled them.